This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial spondyloarthritis, microcystic lymphatic malformations, pulmonary arterial hypertension, and obesity. Here's a closer look at the details. FDA Approvals & Rejections Armata Pharma Secures FDA QIDP Designation for AP-SA02 Armata Pharmaceuticals, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41259 ARCELLX, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-2855917 (State or other jurisdiction of incorp ...

Negative P/E ratio of -29.54 indicates current unprofitability.Low debt-to-equity ratio of 0.12 suggests a conservative approach to debt.High price-to-sales ratio of 183.24 reflects significant market expectations for future growth.ACLX (NASDAQ:ACLX), is currently navigating through financial challenges, highlighted by its negative price-to-earnings (P/E) ratio of -29.54, signaling that the company is not profitable at this time. Despite this, ACLX exhibits a low debt-to-equity ratio of 0.12, indicating a c ...

Key Takeaways GILD will acquire Arcellx for $115 per share plus a $5 CVR, valuing the deal at $7.8 billion.The deal centers on anito-cel, a BCMA CAR-T therapy under FDA review with a December 2026 decision date.GILD expects the acquisition to be accretive from 2028 and strengthen its oncology and cell therapy portfolio.Gilead Sciences, Inc. (GILD) announced that it will acquire a clinical-stage biotechnology company, Arcellx (ACLX) , for $115 per share in cash plus a $5 contingent value right, implying an e ...

吉利德科学同意以每股115美元现金加未来还有机会额外获得的每股最高5美元的或有付款（隐含价值78 亿美元）收购Arcellx，获得其用于多发性骨髓瘤的BCMA CAR-T疗法anito-cel的完全控制权，该药物的 FDA PDUFA日期为2026年12月23日。 责任编辑：张俊 SF065 吉利德科学同意以每股115美元现金加未来还有机会额外获得的每股最高5美元的或有付款（隐含价值78 亿美元）收购Arcellx，获得其用于多发性骨髓瘤的BCMA CAR-T疗法anito-cel的完全控制权，该药物的 FDA PDUFA日期为2026年12月23日。 责任编辑：张俊 SF065 ...

Cory Kasimov from Evercore ISI set a price target of $115 for NASDAQ:ACLX, indicating a slight 1.04% difference from its current trading price.Gilead Sciences plans to acquire Arcellx for up to $7.8 billion, aiming to enhance its cancer treatment portfolio.The acquisition news has led to a significant increase in ACLX's stock price, soaring 77.8% in premarket trading and reflecting a 77.50% rise to $113.80.Arcellx, listed on the NASDAQ:ACLX, is a biotechnology company focused on developing innovative cancer ...

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Arcellx, Inc. to Gilead Sciences, Inc. to assess the adequacy of the price and process involved in the transaction [1] Group 1: Proposed Transaction Details - Under the terms of the proposed sale, shareholders of Arcellx will receive $115.00 per share in cash, along with one contingent value right of $5.00 per share contingent on achieving certain milestones [1] - The investigation aims to determine whether the proposed consideration undervalues Arcellx and if the process leading to this valuation was adequate [1] Group 2: Legal Rights and Actions - Shareholders who believe the transaction undervalues the company are encouraged to discuss their legal rights with Kahn Swick & Foti, LLC [1] - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [1]

Core Viewpoint - Arcellx, Inc. is experiencing significant market activity due to Gilead Sciences' planned acquisition, which is valued at $7.8 billion, marking a pivotal moment for the company and its stock performance [2][4]. Group 1: Stock Performance - Arcellx's stock surged approximately 80% in premarket trading following the acquisition announcement, with the current stock price at $113.81, reflecting a 77.52% increase and a $49.70 change [2]. - The stock has fluctuated between $113.80 and $114.26, marking its highest price over the past year, compared to a previous low of $47.86, indicating substantial growth [3]. Group 2: Acquisition Details - Gilead Sciences plans to acquire Arcellx in an all-cash deal valued at $7.8 billion, which is Gilead's largest acquisition since 2020, aimed at enhancing its cancer treatment portfolio [2]. - The acquisition involves acquiring the remaining shares of Arcellx, further solidifying Gilead's position in the biotech sector [4]. Group 3: Market Capitalization and Trading Volume - Arcellx's market capitalization is approximately $6.58 billion, with a trading volume of around 18.59 million shares, reflecting strong investor interest following the acquisition news [4].

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 23, 2026 /PRNewswire/ -- Class Action Attorney [Juan Monteverde] with [Monteverde & Associates PC](the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is i ...

-- Here's Why Shares of Arcellx Are Up Almost 80% Today [Stocks Tumble Amid Tariff Uncertainty][Trump's 'Plan B' on Tariffs: More Tariffs][Economy Grew Far Less Than Expected in Q4][Inflation Likely to Keep Fed from Cutting Rates Soon]- Top StoriesShares of Arcellx jumped Monday as stocks retreated broadly.Michael M. Santiago / Getty ImagesClose### Key Takeaways- Monday's jump, of about 80%, in Arcellx shares brought them to new highs, exceeding their late-2024 record levels.- Shares of biotech Arcellx vaul ...